New approaches to the treatment of anemia in patients on dialysis: HIF-PH inhibitors and personalized management
Anemia in patients undergoing dialysis has a multifactorial pathogenesis. Currently, the available treatments for renal anemia include erythropoiesis-stimulating agents (ESAs) and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Numerous randomized controlled trials and meta-analyses have demonstrated...